Literature DB >> 11586025

Transient and partial effect of high-dose intravenous immunoglobulin in polyarteritis nodosa.

M Kroiss1, U Hohenleutner, C Gruss, A Glaessl, M Landthaler, W Stolz.   

Abstract

A 57-year-old male patient suffered from polyarteritis nodosa. He presented with articular pain, polyneuropathy, subcutaneous nodules and nodes on the lower legs. After several immunosuppressive agents (methotrexate, mycophenolate mofetil and prednisolone) had proven to be ineffective, 2 g intravenous immunoglobulin (IVIG) per kilogram body weight were administered within 2 days in combination with 10 mg prednisolone per day. Subsequently, 6 cycles of IVIG were applied in increasing intervals from 4 to 6 weeks resulting in a minimum dosage of 0.33 g/kg/week IVIG. The polyarteritis improved within a few days after the first IVIG application. The intensity of polyneuropathy and arthralgia of polyarteritis decreased during the period of IVIG treatment. Finally, a dose reduction of less than 0.25 g/kg/week IVIG resulted in recurring polyarteritis nodosa, which could not be controlled by further administration of IVIG. Therefore, our data indicate that: (1) IVIG is partially effective in cases of polyarteritis nodosa, but the therapeutic effect is only transient; (2) the success of treatment may be correlated with the dose of IVIG per body weight and week; (3) the efficacy/cost ratio of IVIG in polyarteritis nodosa appears to be low. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586025     DOI: 10.1159/000051741

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  7 in total

1.  High-dose intravenous immunoglobulin infusion in polyarteritis nodosa: report on one case and review of the literature.

Authors:  Yoshihide Asano; Hironobu Ihn; Takeo Maekawa; Takafumi Kadono; Kunihiko Tamaki
Journal:  Clin Rheumatol       Date:  2005-10-19       Impact factor: 2.980

Review 2.  [Orphan diseases in rheumatology. Exemplified by polyarteritis nodosa].

Authors:  A Rubbert-Roth
Journal:  Z Rheumatol       Date:  2012-02       Impact factor: 1.372

Review 3.  Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders.

Authors:  Andreas Steinbrecher; Peter Berlit
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

4.  Polyarteritis nodosa and Henoch-Schönlein purpura nephritis in a child with familial Mediterranean fever: a case report.

Authors:  Ilknur Girisgen; Ferah Sonmez; Kutsi Koseoglu; Seda Erisen; Dilek Yilmaz
Journal:  Rheumatol Int       Date:  2011-01-23       Impact factor: 2.631

5.  Intravenous immunoglobulin therapy in vasculitic ulcers: a case of polyarteritis nodosa.

Authors:  Petra M Pego; Inês Aguiar Câmara; José Pedro Andrade; João Matos Costa
Journal:  Auto Immun Highlights       Date:  2013-02-27

6.  Clinical presentations and long term prognosis of childhood onset polyarteritis nodosa in single centre of Korea.

Authors:  Jeong-Seon Lee; Joong-Gon Kim; Soyoung Lee
Journal:  Sci Rep       Date:  2021-04-16       Impact factor: 4.379

Review 7.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.